Profund Advisors LLC Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Profund Advisors LLC boosted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 6.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 120,729 shares of the biopharmaceutical company’s stock after purchasing an additional 7,288 shares during the period. Profund Advisors LLC’s holdings in Amicus Therapeutics were worth $1,516,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Exchange Traded Concepts LLC purchased a new position in Amicus Therapeutics during the 2nd quarter valued at about $77,000. Point72 Middle East FZE purchased a new position in Amicus Therapeutics during the 4th quarter valued at about $81,000. Belpointe Asset Management LLC increased its holdings in Amicus Therapeutics by 1,013.1% during the 1st quarter. Belpointe Asset Management LLC now owns 9,172 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 8,348 shares during the period. Engineers Gate Manager LP purchased a new position in shares of Amicus Therapeutics during the 3rd quarter worth approximately $106,000. Finally, Seven Eight Capital LP purchased a new position in shares of Amicus Therapeutics during the 1st quarter worth approximately $116,000.

Insider Activity

In other news, Chairman John F. Crowley sold 6,043 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $10.84, for a total value of $65,506.12. Following the completion of the sale, the chairman now directly owns 889,834 shares in the company, valued at approximately $9,645,800.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Chairman John F. Crowley sold 6,043 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $10.84, for a total value of $65,506.12. Following the completion of the sale, the chairman now directly owns 889,834 shares in the company, valued at approximately $9,645,800.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman John F. Crowley sold 6,044 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $12.98, for a total value of $78,451.12. Following the completion of the sale, the chairman now owns 920,053 shares of the company’s stock, valued at $11,942,287.94. The disclosure for this sale can be found here. Insiders have sold 77,756 shares of company stock valued at $915,175 in the last ninety days. 2.10% of the stock is currently owned by company insiders.

Amicus Therapeutics Stock Performance

FOLD stock opened at $11.04 on Tuesday. The stock’s 50 day simple moving average is $11.32 and its 200 day simple moving average is $12.14. The stock has a market capitalization of $3.24 billion, a PE ratio of -18.71 and a beta of 0.87. The company has a current ratio of 2.73, a quick ratio of 2.40 and a debt-to-equity ratio of 2.96. Amicus Therapeutics, Inc. has a 12-month low of $9.70 and a 12-month high of $14.10.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. The firm had revenue of $103.50 million for the quarter, compared to analysts’ expectations of $102.30 million. Amicus Therapeutics had a negative return on equity of 147.61% and a negative net margin of 46.61%. The company’s revenue was up 26.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.12) EPS. As a group, research analysts forecast that Amicus Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on FOLD shares. Morgan Stanley upped their price target on Amicus Therapeutics from $14.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 9th. Bank of America upped their price objective on Amicus Therapeutics from $16.00 to $19.00 in a research report on Friday, September 29th. StockNews.com began coverage on Amicus Therapeutics in a research report on Thursday, October 5th. They issued a “hold” rating on the stock. Finally, JPMorgan Chase & Co. upped their price objective on Amicus Therapeutics from $17.00 to $19.00 and gave the company an “overweight” rating in a research report on Friday, September 29th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.17.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.